• Services for Regulatory ATMP Development
    Services for Regulatory ATMP Development

    Living biotherapeutics - Oncolytic viruses - AAV vectors

  • ATMP Biodistribution and Shedding Analysis
    ATMP Biodistribution and Shedding Analysis

    qPCR - CFU determination - Flow cytometry - EliSpot

  • MultiPlex miRNA Biomarker Discovery
    MultiPlex miRNA Biomarker Discovery

    Hydrogel particle-based >65-plex from small samples amounts

  • MultiPlex miRNA Clinical Profiling
    MultiPlex miRNA Clinical Profiling

    Pre-designed & custom >65-plex panels

Accelero Reports 2020 Financial Results and 2021 Forecast

Accelero Bioanalytics GmbH (“Accelero”) announced key figures for the fiscal year 2020 in Germany´s Federal Gazette.

Accelero Receives EU Eurostars Funding Supporting a Gene Therapy for the Treatment of Lypodystrophy

Accelero Bioanalytics GmbH (“Accelero”) is awarded EUR 136,500 in project grants to support research and development of a gene therapy targeting lypodystrophy.

Accelero Receives Authority Permit for SARS-CoV-2 Testing

Accelero Bioanalytics GmbH (“Accelero”) has received the authority permit for processing and analysis of SARS-CoV-2 in biological samples.

Accelero Signs Service Agreement for AAV-Based Gene Therapy Development

Accelero Bioanalytics GmbH (“Accelero”) signed an agreement with the gene therapy company CombiGene AB, Lund, Sweden (“CombiGene”) to support the non-clinical development of an Adeno-associated virus (AAV) with its bioanalytical and regulatory expertise.

Accelero Sustaining Member of the CONELIS Competence Network Life Science

Accelero is pleased to announce that the company has been selected as a sustaining member of the CONELIS network life science. The CONELIS network accumulates top-class consulting services for the biotechnology and pharmaceutical industry.

Accelero Participates in TRAIN-HEART Marie Curie Program Discovering RNA Therapeutics for Heart Failure

Accelero is pleased to announce that the company participates as a partner organization in the Marie Curie TRAIN-HEART consortium funded by the European Commission.

GLP Certificate Refreshed on 15 March 2019

Accelero Bioanalytics GmbH, a Berlin-based GLP certified bioanalytical service provider, announces today that the GLP certificate first issued in 2016 has now been renewed by the competent authority for another three years. The re-inspection has been conducted in November 2018.

Accelero Initiates Clinical Study to Collect Human Wound Fluid

The company is pleased to initiate its first formal clinical study at one of the breast cancer centres in Berlin, Germany. The study is entitled “Post-operative wound fluid collected from female breast cancer patients” and has been approved by the clinical ethics committee.

Accelero Launches Complementary Website

Acccelero Bioanalytics GmbH, a GLP certified contract research laboratory in Berlin, Germany, announces today the publication of the supplementary website binding-assay.com.

Accelero Sees 23% Sales Revenue Increase in 2017 - 9% Operating Profit Margin

Accelero Bioanalytics GmbH is a GLP certified contract research service provider for regulatory drug development, and maintains biosafety level 2 laboratories in compliance with ICH GCP regulations.